Skip to main content
Erschienen in: Cancer Chemotherapy and Pharmacology 4/2009

01.03.2009 | Original Article

Inhibition of NF-κB-mediated transcription and induction of apoptosis in human breast cancer cells by epoxypseudoisoeugenol-2-methyl butyrate

verfasst von: Guoyi Ma, Nurhayat Tabanca, K. Husnu Can Baser, Nese Kirimer, David S. Pasco, Ikhlas A. Khan, Shabana I. Khan

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 4/2009

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Breast cancer is one of the most prevalent woman cancers. Genomic instability, accumulative mutations, and subsequent changes in intracellular signaling cascades play key roles in the development of human breast cancers. Activation of nuclear factor-κB (NF-κB) has been implicated in oncogenesis of breast cancers and is known to be associated with resistance to anticancer agents and apoptosis. Blocking NF-κB signaling may represent a therapeutic strategy in breast cancer therapy. The objective of this study is to investigate the in vitro effects of epoxypseudoisoeugenol-2-methyl butyrate (EPB), a phenylpropranoid isolated from Pimpinella corymbosa, on the activation of NF-κB, cell growth, cell cycle progression and apoptosis in MCF-7 (estrogen-dependent) and BT-549 (estrogen-independent) breast cancer cells.

Methods

Transcriptional activity of NF-κB was measured by cell based reporter gene assay. Cell proliferation was determined by MTT assay. Cell cycle analysis was carried out by flow cytometry and apoptosis was observed by DAPI staining assy.

Results

EPB inhibited the NF-κB-mediated transcription activity induced by tumor necrosis factor-α (TNF-α) and phorbol myristate acetate (PMA) in MCF-7 cells. EPB also inhibited constitutive NF-κB transcriptional activity in BT-549 cells. EPB inhibited the proliferation of both MCF-7 and BT-549 cells in a concentration- and time-dependent manner. EPB induced cell cycle arrest in G1/G0 phase and apoptosis in both MCF-7 and BT 549 cells.

Conclusions

These in vitro results indicated that EPB has a potential for use against both hormone-dependent and hormone-independent breast cancers and its effects seem to be mediated by inhibiting the NF-κB activity.
Literatur
1.
Zurück zum Zitat Merrill RP, Weed DL (2001) Measuring the public health burden of cancer in the United States through lifetime and age-condition risk estimates. Ann Epidemiol 11:547–553PubMedCrossRef Merrill RP, Weed DL (2001) Measuring the public health burden of cancer in the United States through lifetime and age-condition risk estimates. Ann Epidemiol 11:547–553PubMedCrossRef
2.
Zurück zum Zitat Perera NM, Gui GP (2003) Multi-ethnic differences in breast cancer: current concepts and future directions. Int J Cancer 106:463–467PubMedCrossRef Perera NM, Gui GP (2003) Multi-ethnic differences in breast cancer: current concepts and future directions. Int J Cancer 106:463–467PubMedCrossRef
3.
Zurück zum Zitat Cornelissc CJ, Cornelis RS, Devilee P (1996) Gene responsible for familial breast cancer. Pathol Res Practice 192:684–693 Cornelissc CJ, Cornelis RS, Devilee P (1996) Gene responsible for familial breast cancer. Pathol Res Practice 192:684–693
4.
Zurück zum Zitat Somiari RI, Somiari S, Russell S, Shriver CD (2005) Proteomics of breast carcinoma. J Chromatogr B Analyt Technol Biomed Life Sci 815:215–225PubMedCrossRef Somiari RI, Somiari S, Russell S, Shriver CD (2005) Proteomics of breast carcinoma. J Chromatogr B Analyt Technol Biomed Life Sci 815:215–225PubMedCrossRef
5.
Zurück zum Zitat Walczn FG, Krappmann D, Scheidereit C (1978) The NF-kappa B/Rel and I-kappa B gene families: mediators of immune response and inflammation. J Mol Med 74:749–769CrossRef Walczn FG, Krappmann D, Scheidereit C (1978) The NF-kappa B/Rel and I-kappa B gene families: mediators of immune response and inflammation. J Mol Med 74:749–769CrossRef
6.
Zurück zum Zitat Baldwin AS (1996) The NF-kappa B and I kappa B proteins: new discoveries and insights. Ann Rev Immunol 14:649–683CrossRef Baldwin AS (1996) The NF-kappa B and I kappa B proteins: new discoveries and insights. Ann Rev Immunol 14:649–683CrossRef
7.
Zurück zum Zitat Pallares J, Martinez-Guitarte JL, Dolcet X, Llobet D, Rue M, Palacios J, Prat J, Matias-Guiu X (2004) Abnormalities in the NF-κB family and related proteins in endometrial carcinoma. J Pathol 204:569–577PubMedCrossRef Pallares J, Martinez-Guitarte JL, Dolcet X, Llobet D, Rue M, Palacios J, Prat J, Matias-Guiu X (2004) Abnormalities in the NF-κB family and related proteins in endometrial carcinoma. J Pathol 204:569–577PubMedCrossRef
8.
Zurück zum Zitat Wu JT, Kral JG (2005) The NF-κB/IκB signaling system: a molecular target in breast cancer therapy. J Surg Res 123:158–169PubMedCrossRef Wu JT, Kral JG (2005) The NF-κB/IκB signaling system: a molecular target in breast cancer therapy. J Surg Res 123:158–169PubMedCrossRef
9.
Zurück zum Zitat Biswas DK, Dai S-C, Cruz A, Weiser B, Graner E, Pardee AB (2001) The nuclear factor kappB (NF-κB): a potential therapeutic target for estrogen receptor negative breast cancer. Proc Nat Acad Sci USA 98:10386–10391PubMedCrossRef Biswas DK, Dai S-C, Cruz A, Weiser B, Graner E, Pardee AB (2001) The nuclear factor kappB (NF-κB): a potential therapeutic target for estrogen receptor negative breast cancer. Proc Nat Acad Sci USA 98:10386–10391PubMedCrossRef
10.
Zurück zum Zitat Cao Y, Karin M (2003) NF-kappa B in mammary gland development and breast cancer. J Mam Gland Biol Neop 8:215–223CrossRef Cao Y, Karin M (2003) NF-kappa B in mammary gland development and breast cancer. J Mam Gland Biol Neop 8:215–223CrossRef
11.
Zurück zum Zitat Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet RJ Jr, Sledge GW Jr (1997) Constitutive activation of NF-κB during progression of breast cancer to hormone-independent growth. Mol Cell Biol 17:3629–3639PubMed Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet RJ Jr, Sledge GW Jr (1997) Constitutive activation of NF-κB during progression of breast cancer to hormone-independent growth. Mol Cell Biol 17:3629–3639PubMed
12.
Zurück zum Zitat Sovak MA, Bellas RE, Kim DW, Zanieski GJ, Rogers AE, Traish AM, Sonenshein GE (2004) Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer. J Clin Invest 100:2952–2956CrossRef Sovak MA, Bellas RE, Kim DW, Zanieski GJ, Rogers AE, Traish AM, Sonenshein GE (2004) Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer. J Clin Invest 100:2952–2956CrossRef
13.
Zurück zum Zitat Jordan VC, Third annual William L (1995) McGuire memorial lecture. “Studies on the estrogen receptor in breast cancer”—20 years as a target for the treatment and prevention of cancer. Breast Cancer Res Treat 36:267–286PubMedCrossRef Jordan VC, Third annual William L (1995) McGuire memorial lecture. “Studies on the estrogen receptor in breast cancer”—20 years as a target for the treatment and prevention of cancer. Breast Cancer Res Treat 36:267–286PubMedCrossRef
14.
Zurück zum Zitat Hedden A, Muller V, Jensen EV (1995) A new interpretation of antiestrogen action. Ann NY Acad Sci 761:109–120PubMedCrossRef Hedden A, Muller V, Jensen EV (1995) A new interpretation of antiestrogen action. Ann NY Acad Sci 761:109–120PubMedCrossRef
15.
Zurück zum Zitat Santos PM, Figueiredo AC, Oliverira MM, Barroso JG, Pedro lG, Deans SG, Tounus AKM, Scheffer JC (1999) Morphological Stability of Pimpinella anisum hairy root cultures and time-course study of their essential oils. Biotech Lett 21:859–864CrossRef Santos PM, Figueiredo AC, Oliverira MM, Barroso JG, Pedro lG, Deans SG, Tounus AKM, Scheffer JC (1999) Morphological Stability of Pimpinella anisum hairy root cultures and time-course study of their essential oils. Biotech Lett 21:859–864CrossRef
16.
Zurück zum Zitat Bisset NG (2001) (ed) Herbal drugs and phytopharmaceuticals, CRC Press, London, pp 72–75 and pp 375–377 Bisset NG (2001) (ed) Herbal drugs and phytopharmaceuticals, CRC Press, London, pp 72–75 and pp 375–377
17.
Zurück zum Zitat Tabanca N, Bedir E, Kirimer N, Baser KHC, Khan SI, Jacob MR, Khan IA (2003) Antimicrobial compounds from Pimpinella species growing in Turkey. Planta Medica 69:933–938PubMedCrossRef Tabanca N, Bedir E, Kirimer N, Baser KHC, Khan SI, Jacob MR, Khan IA (2003) Antimicrobial compounds from Pimpinella species growing in Turkey. Planta Medica 69:933–938PubMedCrossRef
18.
Zurück zum Zitat Tabanca N, Khan SI, Bedir E, Annavarapu S, Willet K, Khan IA, Kirimer N, Baser KHC (2004) Estrogenic activity of isolated compounds and essential oils of Pimpinella species from Turkey, evaluated using a recombinant yeast screen. Planta Medica 70:728–735PubMedCrossRef Tabanca N, Khan SI, Bedir E, Annavarapu S, Willet K, Khan IA, Kirimer N, Baser KHC (2004) Estrogenic activity of isolated compounds and essential oils of Pimpinella species from Turkey, evaluated using a recombinant yeast screen. Planta Medica 70:728–735PubMedCrossRef
19.
Zurück zum Zitat Tabanca N, Bedir E, Ferraira D, Slade D, Wedge DE, Jacob MR, Khan SI, Khan IA, Kirimer N, Baser KHC (2005) Bioactive constituents from Pimpinella species growing in Turkey. Chemi Biodivers 2:221–232CrossRef Tabanca N, Bedir E, Ferraira D, Slade D, Wedge DE, Jacob MR, Khan SI, Khan IA, Kirimer N, Baser KHC (2005) Bioactive constituents from Pimpinella species growing in Turkey. Chemi Biodivers 2:221–232CrossRef
20.
Zurück zum Zitat Tabanca N, Ma G, Pasco DS, Bedir E, Kirimer N, Baser KHC, Khan IA, Khan SI (2007) Effect of essential oils and isolated compounds from Pimpinella species on NF-κB: a target for anti-inflammatory therapy. Phytother Res 21:741–745PubMedCrossRef Tabanca N, Ma G, Pasco DS, Bedir E, Kirimer N, Baser KHC, Khan IA, Khan SI (2007) Effect of essential oils and isolated compounds from Pimpinella species on NF-κB: a target for anti-inflammatory therapy. Phytother Res 21:741–745PubMedCrossRef
21.
Zurück zum Zitat Chang CC, Zhang J, Lombardi L, Neri A, Dalla-Favera R (1994) Mechanism of expression and role in transcriptional control of the proto-oncogene NFKB–2/LYT-10. Oncogene 9:923–933PubMed Chang CC, Zhang J, Lombardi L, Neri A, Dalla-Favera R (1994) Mechanism of expression and role in transcriptional control of the proto-oncogene NFKB–2/LYT-10. Oncogene 9:923–933PubMed
22.
Zurück zum Zitat Subbaramaiah K, Bulic P, Lin Y, Dannenberg AJ, Pasco DS (2001) Development and use of a gene promoter-based screen to identify novel inhibitors of cyclooxygenase-2 transcription. J Biomol Screening 6:101–110 Subbaramaiah K, Bulic P, Lin Y, Dannenberg AJ, Pasco DS (2001) Development and use of a gene promoter-based screen to identify novel inhibitors of cyclooxygenase-2 transcription. J Biomol Screening 6:101–110
23.
Zurück zum Zitat Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55–63PubMedCrossRef Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55–63PubMedCrossRef
24.
Zurück zum Zitat Ma G, Mustafa J, Khan SI, Walker LA, Khan IA (2005) Anticancer activity and possible mode of action of 4-O-podophyllotoxin-12-Hydroxyl-octadec-Z-9-enoate. Lipids 40:303–308PubMedCrossRef Ma G, Mustafa J, Khan SI, Walker LA, Khan IA (2005) Anticancer activity and possible mode of action of 4-O-podophyllotoxin-12-Hydroxyl-octadec-Z-9-enoate. Lipids 40:303–308PubMedCrossRef
25.
Zurück zum Zitat McGuire WL, Chamnese GC, Fuqua SAW (1991) Estrogen receptor variants in clinical breast cancer. Mol Endocrinol 5:1571–1577PubMedCrossRef McGuire WL, Chamnese GC, Fuqua SAW (1991) Estrogen receptor variants in clinical breast cancer. Mol Endocrinol 5:1571–1577PubMedCrossRef
26.
Zurück zum Zitat Santen R, Manni A, Harvey H, Redmond C (1990) Endocrine treatment of breast cancer in women. Endocr Rev 11:221–265PubMed Santen R, Manni A, Harvey H, Redmond C (1990) Endocrine treatment of breast cancer in women. Endocr Rev 11:221–265PubMed
27.
Zurück zum Zitat Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet RJ Jr, Sledge G Jr (1997) Constitutive activation of NF-κB during progression of breast cancer to hormone-independent growth. Mol Cell Biol 17:3629–3639PubMed Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet RJ Jr, Sledge G Jr (1997) Constitutive activation of NF-κB during progression of breast cancer to hormone-independent growth. Mol Cell Biol 17:3629–3639PubMed
28.
Zurück zum Zitat Bm Rayet, Gelinas C (1999) Aberrant rel/NF-kB genes and activity in human cancer. Oncogene 18:6938–6947CrossRef Bm Rayet, Gelinas C (1999) Aberrant rel/NF-kB genes and activity in human cancer. Oncogene 18:6938–6947CrossRef
29.
Zurück zum Zitat Bourrs V, Dejardin E, Goujon-Letawe F, Merville MP, Castronovo V (1994) The NF-κB- and IκB-related proteins in tumor cell lines. Biochem Pharmacol 47:145–149CrossRef Bourrs V, Dejardin E, Goujon-Letawe F, Merville MP, Castronovo V (1994) The NF-κB- and IκB-related proteins in tumor cell lines. Biochem Pharmacol 47:145–149CrossRef
30.
Zurück zum Zitat Hinz M, Krappmann D, Eichten A, Heder A, Scheidereit C, Strauss M (1999) NF-kappa B function in growth control: regulation of cyclin D1 expression and G0/G1-to-S-phase transition. Mol Cell Biol 19:2690–2698PubMed Hinz M, Krappmann D, Eichten A, Heder A, Scheidereit C, Strauss M (1999) NF-kappa B function in growth control: regulation of cyclin D1 expression and G0/G1-to-S-phase transition. Mol Cell Biol 19:2690–2698PubMed
31.
Zurück zum Zitat Joyce D, Albanese C, Steer J, Fu M, Bouzahzah B, Pestell RG (2001) NF-kappa B and cell cycle regulation: the cyclin connection. Cytokine Growth Factor Rev 12:73–90PubMedCrossRef Joyce D, Albanese C, Steer J, Fu M, Bouzahzah B, Pestell RG (2001) NF-kappa B and cell cycle regulation: the cyclin connection. Cytokine Growth Factor Rev 12:73–90PubMedCrossRef
32.
Zurück zum Zitat Guttridge DC, Albanese C, Reuther JY, Pestell RG, Baldwin AS Jr (1999) NF-κB control cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol 19:5785–5799PubMed Guttridge DC, Albanese C, Reuther JY, Pestell RG, Baldwin AS Jr (1999) NF-κB control cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol 19:5785–5799PubMed
33.
Zurück zum Zitat Bours V, Bentires-Alj M, Hellin AC, Viatour P, Robe P, Delhalle S, Benoit V, Merville MP (2000) Nuclear factor-kappa B, cancer, and apoptosis. Biochem Pharmacol 60:1085–1089PubMedCrossRef Bours V, Bentires-Alj M, Hellin AC, Viatour P, Robe P, Delhalle S, Benoit V, Merville MP (2000) Nuclear factor-kappa B, cancer, and apoptosis. Biochem Pharmacol 60:1085–1089PubMedCrossRef
34.
Zurück zum Zitat Cho MK, Park JW, Jang YP, Kim YC, Kim SG (2002) Potent inhibition of lipopoly-saccharide-inducible nitric oxide synthase expressed by dibenzylbutyroll-actone ligans through inhibition of IκBα phosphorylation and of p65 nuclear translocation in macrophages. Int Immunopharmacol 2:105–116PubMedCrossRef Cho MK, Park JW, Jang YP, Kim YC, Kim SG (2002) Potent inhibition of lipopoly-saccharide-inducible nitric oxide synthase expressed by dibenzylbutyroll-actone ligans through inhibition of IκBα phosphorylation and of p65 nuclear translocation in macrophages. Int Immunopharmacol 2:105–116PubMedCrossRef
Metadaten
Titel
Inhibition of NF-κB-mediated transcription and induction of apoptosis in human breast cancer cells by epoxypseudoisoeugenol-2-methyl butyrate
verfasst von
Guoyi Ma
Nurhayat Tabanca
K. Husnu Can Baser
Nese Kirimer
David S. Pasco
Ikhlas A. Khan
Shabana I. Khan
Publikationsdatum
01.03.2009
Verlag
Springer-Verlag
Erschienen in
Cancer Chemotherapy and Pharmacology / Ausgabe 4/2009
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-008-0784-9

Weitere Artikel der Ausgabe 4/2009

Cancer Chemotherapy and Pharmacology 4/2009 Zur Ausgabe

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.